PRA-133871 (part 1) Duchenne Muscular Dystrophy € 827,-

Full

Description

Study of a new compound that is being developed for the treatment of Duchenne Muscular Dystrophy

Requested participants

  • Male, healthy, 18 - 45 years old

Duration and visits

  • 5 days stay

Learn more about this research?

Research details

Particulars

  • For this study we are looking for healthy Caucasian males between the age of 18 and 45 years.
  • Your Body Mass Index (BMI) has to be between 18.5 and 30.0 kg/m2 and your body weight must be at least 50 kg. The BMI shows the relation between the bodyweight in kilograms and the body length in meters. 
  • Both light smokers and non-smokers are allowed to participate. However, smoking in the clinic is not allowed.
  • To determine if you are suitable to participate in this study, you will undergo medical screening. Before the medical screening you will visit the medical screening center for a short visit to have a blood sample taken to determine what your metabolism is.
Calculate BMI

Compensation

You will receive a gross compensation of €827,- for participation in one of the groups below and you will receive €25,- extra for the short visit.

Traveling expenses will be reimbursed based on kilometers   (€ 0,19 net per kilometer) with a minimum of € 12,- and a maximum of € 160,- (840 kilometers) per return, regardless of the mode of transportation.

Period of stay and research

The study consists of one period in which you will stay in our research facility in Groningen for 5 days (4 nights).

Information sheet PRA-133871 (part 1)

Type of study

The purpose of the study is to investigate to what extent the study medication is safe and tolerated. It will also be investigated how quickly and to what extent the study medication is absorbed and eliminated from the body. The study drug is not registered as a drug and has not been given to humans before. The study is already approved by the Independent Ethics Committee.

This study consists of two parts; Part 1 and Part 2. The remainder of this document only refers to Part 1.

Setup and duration of the study

Part 1 of this study will consist of 1 period during which you will stay in our clinical research center in Groningen, UMCG location for 5 days (4 nights). During Part 1 of this study you will receive the study drug or placebo once in the form of an oral tablet.

Blood samples will be taken and urine will be collected regularly during the study.

Risks and medical supervision

Duchenne’s disease causes irreversible damage of muscle tissue and therefore muscle weakness. This muscle weakness is caused by a low calcium concentration in the muscles. The study drug causes the calcium levels to stay on a certain level, so the damage to muscle tissue and muscle weakness could be prevented.

Adverse effects observed during the first parts were: headache, nausea, abdominal pain, stomachache, bloating, flatulence, stomach discomfort, hunger, dry mouth, muscle pain, pain arms, chest muscle stiffness, muscle cramps and pain in the lower jaw, muscle twitching buttock, muscle cramp thigh, itching both hands, lower back pain, skin irritation at holter and ECG stickers, hematoma at venipuncture site, flu, common cold, nasal congestion, postural dizziness, dizziness, transpiration, sore throat, restlessness, tiredness, sleepiness, anxiety, loose stools, cannula site reaction, increased frequency urination, salivation increased, fast heartbeat, nosebleed, pink eye, sore eye, toothache, higher blood levels of liver enzymes, fungal infection in lower part of the esophagus, and erosion of the intestinal wall in the first part of the duodenum and the stomach wall. At this time it is not known if these effects are related to the study compound as the study is still blinded.

You will be under strict medical supervision during the study. Before the study and at the end of the study you will undergo an extensive medical screening in Groningen.

Conditions for participation

You are a healthy male between 18 and 45 years old. You can only participate in this study if you do nog smoke or smoke less than 5 cigarettes per day. Since the metabolism of the drug in the body can vary based on ethnicity, only caucasion volunteers can participate. Means, you belong to or originates from one of the original people of Europe, the Middle east or North Africa, or the Indian subcontinent.

The study will be executed under standardized conditions. Use of your own medication, alcohol, regular coffee and tea, cola, power drinks, chocolate (including products made of chocolate), grapefruit (juice) and tobacco products during the study is not allowed. Also before the study there will be restrictions for these products.

Use of decaffeinated coffee and (herbal) teas without caffeine is allowed. Before you will take part in the study, you will be medically screened. This screening will take place within four weeks before the start of the study.

Study Dates

Dates for stay in the clinic:

Group 12a:                                            28 January – 01 February 2018

Group 12b:                                            04 – 08 February 2018

Group 12c:                                            27 February – 03 March 2018

The follow up visit will be conducted 2 to 5 days after departure from the research facility.

At entry in the clinic you must have fasted for 4 hours. 

Download PDF
More info Less info

Groep 12a

€ 827,-

5 days stay

  • 25 Feb 2018 up to and including 1 Mar 2018

short stay

Inapplicable
Group full

Groep 12b

€ 827,-

5 days stay

  • 26 Feb 2018 up to and including 2 Mar 2018

short stay

Inapplicable
Group full

Groep 12c

€ 827,-

5 days stay

  • 27 Feb 2018 up to and including 3 Mar 2018

short stay

Inapplicable
Group full

Call me back

We bellen terug tijdens kantooruren binnen 3 werkdagen.

Bel mij terug
  • ?

  • ?